Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702106 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL6702101 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL7002831 | 0.87 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL6705144 | 0.87 | ALDH1A1 (0.47) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL7097211 | 0.79 | PDE7A (0.39) | ALDH1A1L3MBTL1POLBHTT | |
| SCHEMBL7097447 | 0.75 | — | — | |
| SCHEMBL6804691 | 0.71 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL6701095 | 0.71 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL6804689 | 0.71 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL12349572 | 0.66 | ALDH1A1 (0.83) | ALDH1A1MAPTLMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259192-A1 | Method for cleaving the human growth hormone gh | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-12-23 | — | — | US | claimed |
| WO-2002074945-A1 | METHOD FOR CLEAVING HUMAN GROWTH HORMONE GH | IBFB GMBH PRIVATES INSTITUT FÜR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2002-09-26 | — | — | WO | claimed |
| US-20040259192-A1 | Method for cleaving the human growth hormone gh | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-12-23 | — | — | US | disclosed |
| US-20040023953-A1 | Tricylic mercaptomethyl-substituted 2,3-dihydro-quinazolin-5-ones and 2,3-dihydro-benzo-[1,2,4]-thiadiazin-5,5-dioxides as matrix metalloproteinase (MMP) inhibitors | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1319010-B1 | TRICYCLIC MERCAPTOMETHYL-SUBSTITUTED 2,3-DIHYDRO-QUINAZOLIN-5-ONES AND 2,3-DIHYDRO-BENZO-[1,2,4]-THIADIAZIN-5,5-DIOXIDES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS | IBFB GMBH PRIVATES INST FUER B (DE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003089416-A1 | SUBSTITUTED PYRIMIDINE-2,4(1H,3H)-DIONES FOR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS | IBFB GMBH (DE) | 2003-10-30 | — | — | WO | disclosed |
| EP-1357114-A1 | Substituted pyrimidin-2,4(1H,3H)-diones as inhibitors of Matrix Metalloproteinases (MMP) | IBFB GmbH Privates Institut für biomedizinische Forschung und Beratung (DE) | 2003-10-29 | — | — | EP | disclosed |
| EP-1319010-A1 | TRICYCLIC MERCAPTOMETHYL-SUBSTITUTED 2,3-DIHYDRO-QUINAZOLIN-5-ONES AND 2,3-DIHYDRO-BENZO-[1,2,4]-THIADIAZIN-5,5-DIOXIDES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS | IBFB GmbH Privates Institut für biomedizinische Forschung und Beratung (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024710-A1 | TRICYCLIC MERCAPTOMETHYL-SUBSTITUTED 2,3-DIHYDRO-QUINAZOLIN-5-ONES AND 2,3-DIHYDRO-BENZO-[1,2,4]-THIADIAZIN-5,5-DIOXIDES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS | IBFB GMBH PRIVATES INSTITUT FÜR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023953-A1 | Tricylic mercaptomethyl-substituted 2,3-dihydro-quinazolin-5-ones and 2,3-dihydro-benzo-[1,2,4]-thiadiazin-5,5-dioxides as matrix metalloproteinase (MMP) inhibitors | TPSB2, MMP25, MMP15 | ALDH1A1 356/4885MAPT 3416/4885LMNA 4547/4885 |
| US-20040259192-A1 | Method for cleaving the human growth hormone gh | MMP3, MMP25, MMP17 | ALDH1A1 3457/4885MAPT 4820/4885LMNA 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.